[EN] COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS [FR] COMPOSÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES NEURODÉGÉNÉRATIFS, DÉGÉNÉRATIFS ET MÉTABOLIQUES
[EN] PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES USEFUL FOR INHIBITING JANUS KINASE<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-D]PYRIMIDINE UTILES POUR INHIBER LA JANUS KINASE
申请人:PFIZER
公开号:WO2016024185A1
公开(公告)日:2016-02-18
Described herein are pyrrolo2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.
[EN] PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK)<br/>[FR] DÉRIVÉS DE PYRROLO[2,3-D]PYRIMIDINE EN TANT QU'INHIBITEURS DE JANUS KINASES (JAK)
申请人:PFIZER
公开号:WO2014128591A1
公开(公告)日:2014-08-28
Described herein are pyrrolo2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.
An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.
An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.